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Almost 1 in every 100 South Africans is diagnosed with active tuber-
culosis (TB) disease every year, an incidence that ranks among the 
highest of the world’s 22 high-TB-burden countries; TB accounted 
for an astounding 14.6% of deaths among 15 - 44-year-olds in South 
Africa (SA) in 2014.[1] Globally, TB is recognised as the leading cause 
of mortality by an infectious agent, with 1.4 million deaths and 
10.4 million new TB cases in 2015.[2] Although most forms of TB are 
treatable, prompt diagnosis is challenging and passive case-finding 
approaches have failed to control the epidemic. The estimated 80% of 
SA adults who are latently infected with Mycobacterium tuberculosis 
form a massive reservoir for future reactivation cases.[3,4] Indeed, even 
if all new M. tuberculosis infections were prevented, the incidence of 
TB stemming from the global reservoir of 1.7 billion latently infected 
people (23% of the world population) would be 16.5 per 100 000 per-
son-years in 2035, falling short of the 2050 target for eradicating TB.[4] 
As preventive therapy at this scale is not feasible, no single current 
intervention is likely to achieve the goals of The End TB Strategy.[5]
There is an urgent need for earlier TB case identification, using novel 
non-sputum-based diagnostics, linked to more effective preventive 
and curative strategies. A blood-based triage test that allows targeted 
investigation of individuals with active and sub-clinical TB disease, 
including asymptomatic individuals at highest risk of progression 
from latency to disease, could help to shorten the time to treatment 
start, or even prevent incipient disease before symptoms emerge.[6,7] 
The vision of a TB blood test to identify high-risk individuals for 
targeted preventive or curative therapy is within reach.
We recently identified a blood ribonucleic acid (RNA) signature 
capable of predicting TB disease before the onset of symptoms.[8] This 
RNA signature, which measures expression of interferon response 
genes, has been translated into a polymerase chain reaction (PCR) 
test and was independently validated in cohorts from The Gambia 
and SA. The 16-gene PCR test predicted incident TB in adolescents, 
with a specificity of 82% and sensitivity of 70% within a year of testing 
– in the combined training and test sets.[8] To improve throughput 
of the test, we have refined the RNA signature to 11 genes, resulting 
in prognostic specificity of 84% and sensitivity of 71% (area under 
the curve = 0.76) 1 year before the onset of TB disease (A Penn-
Nicholson – unpublished data). The PCR assay has been qualified, 
and engagement is underway with commercial partners to translate 
this test technology to a smaller, simpler, faster and cheaper point-
of-care test. 
Prevention of TB disease arising from latent infection is a key 
requirement to achieving global elimination targets, but the inability to 
detect M. tuberculosis in vivo during latent infection constitutes a major 
hurdle to effective prognostics.[4] The Foundation for Innovative New 
Diagnostics (FIND) has proposed that the target product profile of a 
prognostic test for incident TB should have at least 75% sensitivity and 
75% specificity (and optimally >90% for both).[9] Neither the tuberculin 
skin test nor the interferon-gamma release assay (IGRA) meets this 
minimum standard. For example, if IGRA were used as a prognostic 
test in SA, the number needed to treat (NNT) to prevent one case of 
TB would be 85, based on an assumed 2% cumulative incidence of 
TB over 2 years and 50% effectiveness of isoniazid preventive therapy 
(IPT). However, if the RNA signature performs as predicted, the NNT 
would be more than halved, which might make large-scale, targeted TB 
preventive therapy feasible, even in high-TB-incidence countries.[10,11] 
The RNA signature is being assessed in a clinical trial to identify 
healthy adults at high risk of TB disease, and to test whether targeted 
short-course preventive therapy (3 months of once weekly, high-dose 
isoniazid plus rifapentine (3HP)) can prevent TB disease in indi-
viduals who test positive for the RNA signature. The Correlate of Risk 
(COR) Targeted Intervention Study (CORTIS),[12] currently underway at 
5 sites across SA, intends to screen >10 000 healthy adults for the RNA 
signature and follow 3 200 participants over 15 months for incident 
TB disease. CORTIS tests the hypotheses that high-risk signature-
positive individuals (COR+) will have a higher incidence of active TB 
disease than low-risk signature-negative individuals (COR−); and that 
3HP will reduce the incidence of TB disease in COR+ participants 
compared with COR+ participants under active surveillance. 
The RNA signature might also have diagnostic utility for undiag-
nosed, sub-clinical TB disease when deployed as a triage tool to trigger 
investigation in otherwise healthy, RNA signature-positive individuals. 
We have provisionally demonstrated 93% specificity and 92% sensitiv-
ity to discriminate healthy South Africans with latent M. tuber culosis 
infection from those with active TB disease (F Darboe et al. – unpub-
lished data). Within CORTIS, we will further assess the use of the RNA 
signature to diagnose prevalent TB in HIV-negative adults. If success-
ful, this would enable targeted investigation of RNA signature-positive 
individuals for sub-clinical TB disease, allowing early curative treat-
ment; RNA signature-positive individuals found not to have active dis-
ease would be offered preventive therapy; and those found to be RNA 
signature negative would be spared unnecessary intervention (Fig. 1). 
It is estimated that 11% of South Africans live with HIV; yet, 57% 
of the burden of all TB in SA is borne by those living with HIV.[2] HIV 
infection significantly elevates the risk of TB disease.[13] Performance 
of the RNA signature will also be tested in an observational study of 
SA adults living with HIV, in parallel with CORTIS. If the prognostic 
RNA signature performs as expected, it might also be used to identify 
HIV-positive individuals at highest risk of TB disease within a year of 
testing, and thus trigger initiation of targeted, short-course preventive 
therapy regimens that may in future replace chronic IPT.[14]
Should the CORTIS screen-and-treat strategy prove efficacious 
in predicting and reducing the incidence of TB disease by targeted 
preventive therapy, the critical question is whether implementation 
would be feasible for the SA healthcare system. Key considerations 
are: (i) test performance; (ii) population level impact; (iii) cost/benefit 
ratio; (iv) operational feasibility; and (v) political commitment. RNA 
signature performance is being tested prospectively in CORTIS, but 
preliminary models predict that a TB screen-and-treat strategy that 
reached 30% of HIV-negative SA adults annually could reduce the 
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Fig. 1. Proposed RNA signature screen-and-treat algorithm.
5       January 2017, Vol. 107, No. 1
GUEST EDITORIAL
national TB incidence by 14% (95% confidence interval (CI) 11 - 18%) 
over 5 years. If extended to both HIV-negative and HIV-positive 
people, estimations suggest a reduction in TB incidence of 29% 
(95% CI 24 - 32%), and in TB mortality of 35% (95% CI 29 - 37%), 
within 5 years (R G Sumner and T White – unpublished data). In 
the face of the potential impact, the cost/benefit assessment of such 
a strategy needs to be compared with that of untargeted IPT for all 
latently infected South Africans, which is clearly not feasible. SA 
already has an established health infrastructure for large-scale HIV 
test-and-treat programmes, which could be augmented to enable 
annual community-based screening for TB, using an affordable near-
point-of-care device. Finally, with nearly 100 000 South Africans 
dying from TB in 2015,[2] scientific, pharmaceutical and governmental 
stakeholders have a collective responsibility to act promptly on new 
TB research findings and implement novel strategies to save lives. 
The current inadequate tools for screening, diagnosing, treating and 
preventing TB must be urgently and significantly improved if we are 
to end TB in our lifetime.
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